Envisioning the application of systems biology in cancer immunology

Cancer Immunology: A Translational Medicine Context

Volumn , Issue , 2015, Pages 429-449

  Vera, Julio ^a,b   K Gupta, Shailendra ^c,d   Wolkenhauer, Olaf ^c   Schuler, Gerold ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84939452118     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-662-44006-3_23     Document Type: Chapter

References (82)

1. Vera J, Wolkenhauer O. A system biology approach to understand functional activity of cell communication systems. Methods Cell Biol. 2008;90:399-415.
2. Brooks JD. Translational genomics: the challenge of developing cancer biomarkers. Genome Res. 2012;22(2):183-7.
3. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406(6795):536-40.
4. Van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6.
5. Quackenbush J. Computational approaches to analysis of DNA microarray data. Yearb Med Inform. 2006;1:91-103.
6. Vera J, Wolkenhauer O. Mathematical tools in cancer signalling systems biology. In: Cesario A, Marcus F, editors. Cancer systems biology, bioinformatics and medicine. Dordrecht: Springer; 2011. p. 185-212.
7. Reynolds AR, Tischer C, Verveer PJ, Rocks O, Bastiaens PI. EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation. Nat Cell Biol. 2003;5(5):447-53.
8. Vera J, Schmitz U, Lai X, Engelmann D, Khan FM, Wolkenhauer O, Putzer BM. Kinetic modeling-based detection of genetic signatures that provide chemore- sistance via the E2F1-p73/DNp73-miR-205 network. Cancer Res. 2013;73(12):3511-24.
9. Alexopoulos LG, Saez-Rodriguez J, Cosgrove BD, Lauffenburger DA, Sorger PK. Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteomics. 2010;9(9):1849-65.
10. Rehm M, Huber HJ, Dussmann H, Prehn JH. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J. 2006;25(18):4338-49.
11. Vera J, Bachmann J, Pfeifer AC, Becker V, Hormiga JA, Darias NV, Timmer J, Klingmuller U, Wolkenhauer O. A systems biology approach to analyse amplification in the JAK2-STAT5 signalling pathway. BMC Syst Biol. 2008;2:38.
12. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal. 2009;2(77):ra31.
13. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3(90):90ra59.
14. Witz IP. Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res. 2008;100:203-29.
15. Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143(3): 355-66.
16. Perfahl H, Byrne HM, Chen T, Estrella V, Alarcon T, Lapin A, et al. Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS One. 2011;6(4):e14790.
17. Byrne HM. Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer. 2010;10(3):221-30.
18. Segata N, Blanzieri E, Priami C. Towards the integration of computational systems biology and high- throughput data: supporting differential analysis of microarray gene expression data. J Integr Bioinform. 2008;5(1):87.
19. Nikolov S, Vera J, Schmitz U, Wolkenhauer O. A model-based strategy to investigate the role of microRNA regulation in cancer signalling networks. Theory Biosci. 2011;130(1):55-69.
20. Lai X, Schmitz U, Gupta SK, Bhattacharya A, Kunz M, Wolkenhauer O, Vera J. Computational analysis of target hub gene repression regulated by multiple and cooperative miRNAs. Nucleic Acids Res. 2012;40(18):8818-34.
21. Marin-Sanguino A, Gupta SK, Voit EO, Vera J. Biochemical pathway modeling tools for drug target detection in cancer and other complex diseases. Methods Enzymol. 2011;487:319-69.
22. Wong E, Baur B, Quader S, Huang C-H. Biological network motif detection: principles and practice. Brief Bioinform. 2011;13(2):202-15.
23. Khan FM, Schmitz U, Nikolov S, Engelmann D, Putzer BM, Wolkenhauer O, et al. Hybrid modeling of the crosstalk between signaling and transcriptional networks using ordinary differential equations and multi-valued logic. Biochim Biophys Acta. 2014;1844(1 Pt B):289-98.
24. Vera J, Rath O, Balsa-Canto E, Banga JR, Kolch W, Wolkenhauer O. Investigating dynamics of inhibitory and feedback loops in ERK signalling using power- law models. Mol Biosyst. 2010;6(11):2174-91.
25. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006;232(2):123-38.
26. Pappalardo F, Chiacchio F, Motta S. Cancer vaccines: state of the art of the computational modeling approaches. Biomed Res Int. 2013;2013:106407.
27. Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: looking to the future. Oncoimmunology. 2013;2(3):e23403.
28. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378): 480-9.
29. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22).
30. Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, van der Meer Berends DMA, Vloon APG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838-47.
31. Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A. 2004; 101:14646-52.
32. Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC. Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res. 2013;19(5):1290-9.
33. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237-51.
34. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010;28(21):3525-30.
35. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297-339.
36. Guo K, Li J, Tang JP, Tan CPB, Hong CW, Al-Aidaroos AQO, et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med. 2011;3(99):99ra85.
37. Hong CW, Zeng Q. Awaiting a new era of cancer immunotherapy. Cancer Res. 2012;72(15):3715-9.
38. Caballero OL, Chen Y-T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014-21.
39. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72(5): 1081-91.
40. Charoentong P, Angelova M, Efremova M, Gallasch R, Hackl H, Galon J, et al. Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother. 2012;61(11):1885-903.
41. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208.
42. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1-6.
43. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppliment 3: S3/1-10.
44. De Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17-27.
45. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-9.
46. Wain G. The human papillomavirus (HPV) vaccine, HPV related diseases and cervical cancer in the postreproductive years. Maturitas. 2010;65(3):205-9.
47. Gupta SK, Singh A, Srivastava M, Gupta SK, Akhoon BA. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer. Vaccine. 2009;28(1):120-31.
48. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3-4):213-9.
49. Nielsen M, Lundegaard C, Worning P, Lauem0ller SL, Lamberth K, Buus S, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 2003;12(5): 1007-17.
50. Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics. 2005;6(1):132.
51. Bui H-H, Sidney J, Peters B, Sathiamurthy M, Sinichi Purton K-A, et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics. 2005;57(5): 304-14.
52. Nakamura Y, Gojobori T, Ikemura T. Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res. 2000;28(1):292.
53. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol. 1997;158(8):3635-9.
54. Harish N, Gupta R, Agarwal P, Scaria V, Pillai DyNAVacS: an integrative tool for optimized DNA vaccine design. Nucleic Acids Res. 2006;34(Web Server issue): W264-6.
55. Dolenc I, Seemuller E, Baumeister W. Decelerated degradation of short peptides by the 20S proteasome. FEBS Lett. 1998;434(3):357-61.
56. Chiang HL, Terlecky SR, Plant CP, Dice JF. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science. 1989;246(4928):382-5.
57. Donna LM, Kristala JP. Design of plasmid DNA constructs for vaccines. DNA vaccines. Methods Mol Med™. 2006;127:11-22.
58. Ashall L, Horton CA, Nelson DE, Paszek P, Harper CV, Sillitoe K, et al. Pulsatile stimulation determines timing and specificity of NF-kappaB-dependent transcription. Science. 2009;324(5924):242-6.
59. Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR- 17-92, E2F, and Myc. Proc Natl Acad Sci U S A. 2008;105(50):19678-83.
60. Das J, Ho M, Zikherman J, Govern C, Yang M, Weiss A, et al. Digital signaling and hysteresis characterize ras activation in lymphoid cells. Cell. 2009;136(2): 337-51.
61. Guebel DV, Schmitz U, Wolkenhauer O, Vera J. Analysis of cell adhesion during early stages of colon cancer based on an extended multi-valued logic approach. Mol Biosyst. 2012;8(4):1230-42.
62. Saez-Rodriguez J, Simeoni L, Lindquist JA, Hemenway R, Bommhardt U, Arndt B, et al. A logical model provides insights into t cell receptor signaling. PLoS Comput Biol. 2007;3(8):e163.
63. Carbo A, Hontecillas R, Kronsteiner B, Viladomiu M, Pedragosa M, Lu P, et al. Systems modeling of molecular mechanisms controlling cytokine-driven CD4+ T cell differentiation and phenotype plasticity. PLoS Comput Biol. 2013;9(4):e1003027.
64. Pigliucci M. Genotype-phenotype mapping and the end of the “genes as blueprint” metaphor. Phil Trans R Soc B. 2010;365(1540):557-66.
65. Deisboeck TS, Wang Z, Macklin P, Cristini V. Multiscale cancer modeling. Annu Rev Biomed Eng. 2011;13:127-55.
66. Ramis-Conde I, Drasdo D, Anderson ARA, Chaplain MAJ. Modeling the influence of the E-Cadherin-p- Catenin pathway in cancer cell invasion: a multiscale approach. Biophys J. 2008;95(1):155-65.
67. Pak Y, Zhang Y, Pastan I, Lee B. Antigen shedding may improve efficiencies for delivery of antibody- based anticancer agents in solid tumors. Cancer Res. 2012;72(13):3143-52.
68. Wolkenhauer O, Auffray C, Baltrusch S, Bluthgen N, Byrne H, Cascante M, et al. Systems biologists seek fuller integration of systems biology approaches in new cancer research programs. Cancer Res. 2010;70(1):12-3.
69. Wolkenhauer O, Auffray C, Jaster R, Steinhoff G, Dammann O. The road from systems biology to systems medicine. Pediatr Res [Internet]. [cited 17 Mar 2013]; 2013 http://www.nature.com/pr/journal/vaop/ncurrent/full/pr20134a.html.
70. Engel C, Scholz M, Loeffler M. A computational model of human granulopoiesis to simulate the hema- totoxic effects of multicycle polychemotherapy. Blood. 2004;104(8):2323-31.
71. Ribba B, Colin T, Schnell S. A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Theor Biol Med Model. 2006;3:7.
72. Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol. 2012;7(10):1583-93.
73. Ballesta A, Dulong S, Abbara C, Cohen B, Okyar A, Clairambault J, et al. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput Biol. 2011;7(9):e1002143.
74. Levi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001;2(5):307-15.
75. Vera J, Curto R, Cascante M, Torres NV. Detection of potential enzyme targets by metabolic modelling and optimization: application to a simple enzymopathy. Bioinformatics. 2007;23(17):2281-9.
76. Rateitschak K, Winter F, Lange F, Jaster R, Wolkenhauer O. Parameter identifiability and sensitivity analysis predict targets for enhancement of STAT1 activity in pancreatic cancer and stellate cells. PLoS Comput Biol. 2012;8(12):e1002815.
77. Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal. 2013; 6(288):ra68.
78. Kim PS, Lee PP. Modeling protective anti-tumor immunity via preventative cancer vaccines using a hybrid agent-based and delay differential equation approach. PLoS Comput Biol. 2012;8(10):e1002742.
79. Maley CC, Reid BJ, Forrest S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev. 2004;13(8):1375-84.
80. Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009;69(11):4894-903.
81. Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res. 2012;72(24):6362-70.
82. Dubitzky W, Wolkenhauer O, Yokota H, Cho KH. Encyclopedia of systems biology. New York: Springer; 2013. ISBN 978-1-4419-9862-0.